UK-Based Nanomedicine firm set plans to initiate a large phase II efficacy study in 2019

Fungal Nail Infection (Onychomycosis) is the most common nail disorder.1 Risk factors such as trauma, old age, diabetes, immunosuppression, tinea pedis, psoriasis, and family history are leading to an increased prevalence.2

Onychomycosis is characterised by nail thickening, splitting, roughening and discolouration. Although viewed as ‘less serious’ than other infectious diseases, onychomycosis may cause significant disability, including pain, nerve damage, difficulties performing daily tasks, and has been linked to poor mental health and impaired social interactions.3  

Onychomycosis is notoriously difficult to treat because the dermatophytes grow between the nail bed and plate but are protected by the nail.4 The efficacy of current treatments is limited by the slow growth of toenails, nail keratin thickness preventing penetration of topical and systemic drugs, and survival […]